EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Uncovering Potential Druggable Targets in Coronary Atherosclerosis: A Proteome‐Wide Mendelian Randomization Study With Cross‐Platform and Experimental Validation

Da Gao iD, Haiyan Lin iD, Shengjie Wang iD, Yanwei Wang iD, Hao Yang iD, Zicheng Wang iD

Cardiovascular Therapeutics · 2026

DOI: 10.1155/cdr/7359278 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Da Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China, nbws.gov.cn. Hauptthemen laut MEDLINE: Coronary Artery Disease, Proteomics, Quantitative Trait Loci, Proteome. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Province Health Industry Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronary atherosclerosis (CA) is a leading cause of cardiovascular morbidity and mortality worldwide. This study is aimed at identifying candidate plasma proteins and potential therapeutic targets for CA.

Methods

We performed a proteome‐wide Mendelian randomization (MR) analysis using integrated protein quantitative trait loci (pQTLs) and genome‐wide association study (GWAS) summary data. Forward two‐sample MR was first performed using cis‐pQTLs from the UK Biobank Pharma Proteomics Project (UKB‐PPP), followed by reverse MR analysis to exclude potential reverse causality. Bayesian colocalization analysis was conducted to ensure that the associations between proteins and CA were driven by shared genetic variants. Summary‐data‐based MR (SMR) combined with HEIDI testing was used to prioritize proteins and eliminate linkage bias. Significant proteins were cross‐referenced with a curated druggable genome to identify their potential therapeutic relevance. Cross‐platform validation was performed using the SomaScan‐based pQTL dataset from deCODE genetics. An oxidized low‐density lipoprotein (ox‐LDL)–induced human umbilical vein endothelial cell (HUVEC) injury model was used for the evaluation of prioritized proteins.

Results

Forward MR analysis using UKB‐PPP cis‐pQTL data identified 45 CA‐associated proteins (23 protective, 22 risk‐related; FDR < 0.05), with no reverse causality observed. Five proteins—PARP1, SDCCAG8, FST, FOLH1, and NCAN—were prioritized through MR (FDR < 0.05), colocalization analysis (PP.H4 > 0.50), and SMR analysis with HEIDI filtering ( p _SMR < 0.05; p _HEIDI > 0.05). All five proteins were included in the druggable genome list, supporting their potential therapeutic relevance. PARP1 showed consistent associations across Olink and SomaScan platforms and was upregulated in an ox‐LDL‐induced HUVEC model as assessed by western blot.

Conclusions

This study identified PARP1, SDCCAG8, FST, FOLH1, and NCAN as genetically prioritized candidate proteins for CA, with PARP1 showing the most consistent evidence across analyses. Further validation and mechanistic studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseProteomicsQuantitative Trait LociProteomeCardiovascular AgentsHumansMendelian Randomization AnalysisHuman Umbilical Vein Endothelial CellsGenome-Wide Association StudyReproducibility of ResultsGenetic Predisposition to DiseasePhenotypeLipoproteins, LDL

Stichwörter der Autor:innen

Mendelian randomizationSMR analysiscolocalization analysiscoronary atherosclerosisplasma proteins

Substanzen

Proteomeoxidized low density lipoproteinLipoproteins, LDLCardiovascular Agents

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China, nbws.gov.cn.

ORCID-Profile: Da Gao, Haiyan Lin, Shengjie Wang, Yanwei Wang, Hao Yang, Zicheng Wang

Förderung

  • Zhejiang Province Health Industry Science and Technology Plan Project

Zitieren

APA

Gao, D., Lin, H., Wang, S., Wang, Y., Yang, H., & Wang, Z. (2026). Uncovering Potential Druggable Targets in Coronary Atherosclerosis: A Proteome‐Wide Mendelian Randomization Study With Cross‐Platform and Experimental Validation. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/7359278

Vancouver

Gao D, Lin H, Wang S, Wang Y, Yang H, Wang Z. Uncovering Potential Druggable Targets in Coronary Atherosclerosis: A Proteome‐Wide Mendelian Randomization Study With Cross‐Platform and Experimental Validation. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/7359278

BibTeX
@article{Gao2026,
  author = {Gao, Da and Lin, Haiyan and Wang, Shengjie and Wang, Yanwei and Yang, Hao and Wang, Zicheng},
  title = {Uncovering Potential Druggable Targets in Coronary Atherosclerosis: A Proteome‐Wide Mendelian Randomization Study With Cross‐Platform and Experimental Validation},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  doi = {10.1155/cdr/7359278}
}
Kostenlos starten →